Geriatrics (> 55 years old): Evidence suggests that use in the geriatric population is
associated with differences in safety or effectiveness. Intravenous sedation with …

The MIDnight study carried out in a geriatric hospital confirms the hypothesis of gaps
between recommendations and off-label use of drugs, like midazolam. Such gaps expose …

Midazolam is a short‐acting benzodiazepine approved for sedation and anesthesia
induction. Recent data suggested that midazolam may also be used in off‐label indications …

This systematic review and meta-analysis with trial sequential analysis (TSA) aimed to
evaluate the efficacy and safety of remimazolam compared to other sedatives for procedural …

Introduction Anti-psychotics and benzodiazepines are commonly prescribed for older
people. They are usually indicated in the short term for delirium and agitation. There are …

Objective We investigated the pharmacologic properties of midazolam with special regard to
age using the electroencephalogram (EEG) as a measure of the hypnotic‐sedative effect …

Background Intranasal midazolam can produce procedural sedation in frail older patients
with dementia who are unable to tolerate necessary medical or dental procedures during …

Background: It is unclear how best to measure sedative/analgesic drug exposure in the
clinical care of critically ill patients. Large doses and prolonged use of sedatives and …

Background Given the potentially important effects that age and gender may have on
midazolam premedication, this study aimed at determining if these factors alter anxiety …

Midazolam, the first benzodiazepine derivative with water-soluble salts, was studied as an
induction agent in general anesthesia for the elderly. In group 1 (n= 14), 5 or 10 mg oral …